Insulin levels are decreased in the cerebrospinal fluid of women with prodomal alzheimer's disease

Journal of Alzheimer's Disease

Volumn 22, Issue 2, 2010, Pages 405-413

  Gil Bea, Francisco J ^a   Solas, Maite ^b   Solomon, Alina ^a   Mugueta, Carmen ^c   Winblad, Bengt ^a   Kivipelto, Miia ^a   Ramirez, Maria J ^b   Cedazo Mínguez, Angel ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Alzheimer's disease; cerebrospinal fluid; insulin; mild cognitive impairment; women

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; INSULIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 78650962354     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100795     Document Type: Article

References (45)

1. Banks WA (2004) The source of cerebral insulin. Eur J Pharmacol 490, 5-12.
2. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
3. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268.
4. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR (2000) Role of brain insulin receptor in control of body weight and reproduction. Science 289, 2122-2125.
5. Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1998) Water maze learning and hippocampal synaptic plasticity in streptozotocin- diabetic rats: effects of insulin treatment. Brain Res 800, 125-135.
6. Benedict C, Hallschmid M, Schultes B, Born J, Kern W (2007) Intranasal insulin to improve memory function in humans. Neuroendocrinology 86, 136-142.
7. Fillit H, Nash DT, Rundek T, Zuckerman A (2008) Cardiovascular risk factors and dementia. Am J Geriatr Pharmacother 6, 100-118.
8. Hoyer S, Oesterreich K, Wagner O (1988) Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol 235, 143-148.
9. Hoyer S, Nitsch R, Oesterreich K (1991) Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 3, 1-14.
10. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 101, 3100-3105.
11. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J18, 902-904.
12. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Green- gard P, Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta- amyloid and requires mitogen-activated protein kinase signaling. JNeurosci 21, 2561-2570.
13. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D, Jr. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164168.
14. Fujisawa Y, Sasaki K, Akiyama K (1991) Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 30, 1219-1228.
15. Molina JA, Jimenez-Jimenez FJ, Vargas C, Gomez P, de Bus- tos F, Gomez-Escalonilla C, Zurdo M, Tallon A, Martinez- Salio A, Porta-Etessam J, Villanueva C, Arenas J (2002) Cere- brospinal fluid levels of insulin in patients with Alzheimer's disease. Acta Neurol Scand 106, 347-350.
16. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B (2006) Mild cognitive impairment. Lancet 367, 1262-1270.
17. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234.
18. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680.
19. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245.
20. Vanmechelen E, Vanderstichele H, Davidsson P, Van Ker- schaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
21. Cedazo-Minguez A, Winblad B (2010) Biomarkers for Alzheimer's disease and other forms of dementia: Clinical needs, limitations and future aspects. Exp Gerontol 45, 5-14.
22. Zhao WQ, Townsend M (2009) Insulin resistance and amy- loidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792, 482-496.
23. Stolk RP, Breteler MM, Ott A, Pols HA, Lamberts SW, Grobbee DE, Hofman A (1997) Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care 20, 792-795.
24. Stolk RP, Pols HA, Lamberts SW, de Jong PT, Hofman A, Grobbee DE (1997) Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. Am J Epidemiol 145, 24-32.
25. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61, 661-666.
26. Haan MN (2006) Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2, 159-166.
27. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K (1999) Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70, 146-152.
28. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF (2007) Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68, 1809-1814.
29. Bucht G, Adolfsson R, Lithner F, Winblad B (1983) Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 213, 387-392.
30. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW (2000) Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49, 15251533.
31. Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA, Newton R, Gandy SE, Martins RN (2005) Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis 8, 269-282.
32. Odetti P, Piccini A, Giliberto L, Borghi R, Natale A, Monacelli F, Marchese M, Assini A, Colucci M, Cammarata S, Tabaton M (2005) Plasma levels of insulin and amyloid beta 42 are correlated in patients with amnestic Mild Cognitive Impairment. JAlzheimers Dis 8, 243-245.
33. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
34. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60, 1899-1903.
35. Tamaki C, Ohtsuki S, Terasaki T (2007) Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation oflow-density lipoprotein receptor- related protein 1 (LRP-1) to the plasma membrane in hepato- cytes. Mol Pharmacol 72, 850-855.
36. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV (2007) Clear-ance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13, 1029-1031.
37. Stockinger W, Hengstschlager-Ottnad E, Novak S, Matus A, Huttinger M, Bauer J, Lassmann H, Schneider WJ, Nimpf J (1998) The low density lipoprotein receptor gene family. Differential expression oftwo alpha2-macroglobulin receptors in the brain. J Biol Chem 273, 32213-32221.
38. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24, 11120-11126.
39. Fernandez-Gamba A, Leal MC, Morelli L, Castano EM (2009) Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. Curr Pharm Des 15, 3644-3655.
40. Margolis RU, Altszuler N (1967) Insulin in the cerebrospinal fluid. Nature 215, 1375-1376.
41. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L (1990) Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 81, 323-326.
42. Oztas B, Akgul S, Seker FB (2007) Gender difference in the influence of antioxidants on the blood-brain barrier permeability during pentylenetetrazol- induced seizures in hyperthermic rat pups. Biol Trace Elem Res 118, 77-83.
43. Ito S, Ohtsuki S, Terasaki T (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 56, 246-252.
44. Algotsson A, Winblad B (2007) The integrity of the blood- brain barrier in Alzheimer's disease. Acta Neurol Scand 115, 403-408.
45. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103.